Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages’ transition into a pro-inflammatory state

AIMS: CD40 and its ligand, CD40L, play a critical role in driving atherosclerotic plaque development. Disrupted CD40-signalling reduces experimental atherosclerosis and induces a favourable stable plaque phenotype. We recently showed that small molecule-based inhibition of CD40-tumour necrosis facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosmans, Laura A, van Tiel, Claudia M, Aarts, Suzanne A B M, Willemsen, Lisa, Baardman, Jeroen, van Os, Bram W, den Toom, Myrthe, Beckers, Linda, Ahern, David J, Levels, Johannes H M, Jongejan, Aldo, Moerland, Perry D, Verberk, Sanne G S, van den Bossche, Jan, de Winther, Menno M P J, Weber, Christian, Atzler, Dorothee, Monaco, Claudia, Gerdes, Norbert, Shami, Annelie, Lutgens, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202633/
https://www.ncbi.nlm.nih.gov/pubmed/35587037
http://dx.doi.org/10.1093/cvr/cvac084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202633/
https://www.ncbi.nlm.nih.gov/pubmed/35587037
http://dx.doi.org/10.1093/cvr/cvac084

Ejemplares similares